Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 15:42 ET | Source: Transpire Bio

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic...
February 23, 2026 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
February 19, 2026 17:03 ET | Source: kneat.com, inc.

Global Pharmaceutical Packaging Manufacturer Selects Kneat

Global Pharmaceutical Packaging Manufacturer Selects Kneat for Digital Validation
February 17, 2026 07:00 ET | Source: Essential Pharma

Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension

Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertensionAcquisition reinforces Essential Pharma’s mission to serve the needs of rare disease...
February 12, 2026 21:21 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

The current indications of soficitinib under development are strategically positioned within the vast dermatology market.
February 11, 2026 06:00 ET | Source: AscellaHealth, LLC

AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences

AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences
February 11, 2026 04:00 ET | Source: Rentschler Biopharma SE

Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board

Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1,...
February 10, 2026 16:40 ET | Source: PharmAla Biotech

PharmAla Announces Changes to Board of Directors

PharmAla announces the resignation of Dr. Malik Slassi and the appointment of Mr Lennie Ryer to its board.
February 08, 2026 21:43 ET | Source: InnoCare Pharma

InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

ICP-538 is the first VAV1 degrader approved to enter clinical trials in China and the second globally.
February 04, 2026 07:34 ET | Source: kneat.com, inc.

Kneat to Announce 2025 Fourth-Quarter and Year-End Financial Results February 25, 2026

Kneat will release its financial results for the quarter ended December 31, 2025 on February 25, 2026 and host a conference call on February 26, 2026.